Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Doxepin cream vs oral antihistamine Adverse events (somnolence) · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | RR 0.64 [0.32, 1.25] | 1 study · 24 participants | Very low |
Extracorporeal shock wave therapy vs sham Adverse events · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Extracorporeal shock wave therapy vs sham Pain Pressure pain threshold (PPT) ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | MD 2.96 [1.76, 4.16] | 1 study · 45 participants | Low |
Pulsed high‐intensity laser vs placebo laser Change in burn‐related pruritus Itch Severity Scale (ISS) ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 1 study · 49 participants | Moderate |
Pulsed high‐intensity laser vs placebo laser Adverse events · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Pulsed high‐intensity laser vs placebo laser Pain VAS ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 1 study · 49 participants | Moderate |
Doxepin cream vs oral antihistamine Pain · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs cetirizine (antihistamine) Change in burn‐related pruritus (VAS) ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Gabapentin vs cetirizine (antihistamine) Adverse events (somnolence) · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | RR 0.02 [0, 0.38] | 1 study · 40 participants | Low |
Gabapentin vs cetirizine (antihistamine) Pain · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Pregabalin vs cetirizine with pheniramine maleate (antihistamine) Change in burn‐related pruritus (VAS) ( · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | 1 study · 40 participants | Low |
Pregabalin vs cetirizine with pheniramine maleate (antihistamine) Adverse events (drowsiness) · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | RR 0.04 [0, 0.69] | 1 study · 40 participants | Low |
Pregabalin vs cetirizine with pheniramine maleate (antihistamine) Pain · people with postburn pruritus Interventions for postburn pruritus (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD20 mAb maintenance therapy vs observation Overall survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.94 [0.73, 1.2] | 3 studies · 1152 participants | Moderate |
Immunomodulatory drug maintenance therapy vs placebo/observation Grade 3/4 adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.82 [1.38, 2.38] | 2 studies · 400 participants | Low |
Immunomodulatory drug maintenance therapy vs placebo/observation Progression‐free survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.37 [0.19, 0.73] | 3 studies · 461 participants | Moderate |
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment‐related mortality · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 1.22 [0.35, 4.29] | 3 studies · 458 participants | Low |
Immunomodulatory drug maintenance therapy vs placebo/observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.71 [0.47, 1.05] | 2 studies · 400 participants | Very low |
Immunomodulatory drug maintenance therapy vs placebo/observation All adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.41 [1.28, 1.54] | 3 studies · 458 participants | Moderate |
Anti‐CD52 mAb maintenance therapy vs observation Overall survival – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Grade 3/4 adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation Progression‐free survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.55 [0.32, 0.95] | 1 study · 21 participants | Very low |
Anti‐CD52 mAb maintenance therapy vs observation Treatment‐related mortality – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD20 mAb maintenance therapy vs observation Health‐related quality of life · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | 1 study · 480 participants | Low |
Anti‐CD52 mAb maintenance therapy vs observation Treatment discontinuation – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD52 mAb maintenance therapy vs observation All adverse events – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Anti‐CD20 mAb maintenance therapy vs observation Grade 3/4 adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.34 [1.06, 1.71] | 5 studies · 1284 participants | Low |
Anti‐CD20 mAb maintenance therapy vs observation Progression‐free survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.61 [0.5, 0.73] | 5 studies · 1255 participants | Moderate |
Anti‐CD20 mAb maintenance therapy vs observation Treatment‐related mortality · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.82 [0.39, 1.71] | 4 studies · 1189 participants | Low |
Anti‐CD20 mAb maintenance therapy vs observation Treatment discontinuation · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Risk ratio 0.93 [0.72, 1.2] | 6 studies · 1321 participants | Low |
Anti‐CD20 mAb maintenance therapy vs observation All adverse events · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | Rate ratio 1.23 [1.03, 1.47] | 6 studies · 1321 participants | Low |
Immunomodulatory drug maintenance therapy vs placebo/observation Overall survival · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | HR 0.91 [0.61, 1.35] | 3 studies · 461 participants | Moderate |
Immunomodulatory drug maintenance therapy vs placebo/observation Health‐related quality of life – not reported · people with chronic lymphocytic leukaemia Maintenance therapy for chronic lymphocytic leukaemia (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) vs no treatment/lanolin Scar improvement (VSS) (0–13, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 3 studies · 187 participants | Very low |
Pressure‐garment therapy (PGT) vs silicone Pain (POSAS 0–10, higher score = more severe pain, VAS 0–10, higher score = more severe pruritus) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 2 studies · 263 participants | Very low |
Pressure‐garment therapy (PGT) vs silicone Pruritus (POSAS 0–10, higher score = more severe pruritus; TPIS 0–3, higher score = more severe pruritus; VAS 0–10, higher score = more severe pruritus) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 2 studies · 263 participants | Very low |
Pressure‐garment therapy (PGT) vs silicone Quality of life (CHU‐9D 0–1, with 1 representing full health; BBSIP 0–5, higher scores = more severe impact) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 159 participants | Very low |
Pressure‐garment therapy (PGT) vs silicone Adverse events · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 159 participants | Very low |
Pressure‐garment therapy (PGT) vs silicone Adherence · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 159 participants | Very low |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Scar improvement (VSS) (0–13, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 96 participants | Very low |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Pain (VAS 0–10, higher score = more severe pain) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 104 participants | Very low |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Pruritus (VAS 0–10, higher score = more severe pruritus) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 104 participants | Very low |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Quality of life · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) vs no treatment/lanolin Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Adverse events · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 104 participants | Very low |
Pressure‐garment therapy (PGT) plus silicone vs no treatment/lanolin Adherence · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | NR | No studies |
Pressure‐garment therapy (PGT) plus silicone vs silicone Scar improvement (VSS) (0–13, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 96 participants | Very low |
Pressure‐garment therapy (PGT) plus silicone vs silicone Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring Pressure‐garment therapy for preventing hypertrophic scarring after burn injury (2024) · Cochrane | no estimate extracted | 1 study · 159 participants | Very low |